BioWorld

Feb. 12, 2002

United Therapeutics Receives Remodulin Approvable Letter

Following receipt of an approvable letter from the FDA, United Therapeutics Corp. said its orphan drug for pulmonary arterial hypertension should reach the market sometime in the next two months. (BioWorld Today) Read More

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

One Of 40 Myosin Proteins In Mammalian Body Led Mice To Key Hearing-Mechanism Clue

Inhibitex Closing $41M Round To Fund Product Development

CytRx, Global Genomics Merging In Deal Worth Up To $6.28M

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for April 22, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...